Category: News

Illuminating ctDNA-MRD: Gene Solutions’ K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology

Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology. This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP)

Da Nang, Vietnam – May 9-11, 2025 – Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. —  This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular […]

SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia

SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia

SINGAPORE, May 16, 2025 /PRNewswire/ — In a bold step toward equitable cancer care, Gene Solutions introduces SPOT-MAS Lung, a next-generation blood-based test powered by artificial intelligence (AI) and multi-omics analysis. Designed with lung-specific features, SPOT-MAS Lung may offer a promising approach for earlier detection in Asia—especially among asymptomatic individuals who are often missed by […]

Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan

Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum of Understanding (MoU) at NEWCL's state-of-the-art facility in New Taipei City.

NEW TAIPEI CITY, May 16, 2025 — In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan’s pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum […]

Advanced Genetic Testing in Philippines for Cancer and Baby’s Health Launched Through Gene Solutions & The Medical City Partnership

Gene Solutions has partnered with The Medical City — the largest healthcare network in the Philippines — to bring a state-of-the-art Next-Generation Sequencing (NGS) facility right here at home.

Pasig City, Philippines – April 28, 2025 – Gene Solutions has teamed up with The Medical City (TMC), the largest healthcare network in the Philippines to bring advanced DNA testing closer to Filipino families. Through this partnership, a state-of-the-art Next-Generation Sequencing (NGS) facility is now operational at TMC Ortigas—offering faster, more affordable tests for cancer […]

Gene Solutions and Element Biosciences Enter Strategic Collaboration to Advance Next-Generation Sequencing (NGS) Technology Globally

Gene Solutions and Element Biosciences Enter Strategic Collaboration to Advance Next-Generation Sequencing (NGS) Technology Globally

April 2025 – Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration. The collaboration was formalized with the signing of a Memorandum of Understanding (MoU) during Element Biosciences’ visit at Gene Solutions’ laboratory. 🤝 […]

Asia’s First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring

ctDNA analysis workflow. For patients at early stage I-III, paired tumor FFPE and WBC DNA samples were sequenced to identify tumor-specic mutations in 155 cancer-associated genes. Top personalized mutations with the highest ranking scores were used to detect ctDNA in plasma samples by mPCR and ultradeep sequencing. For patients at metastatic stage IV, besides personalized mutations, an additional panel of approximately 500 hotspot mutations specific to each cancer type was added to the analysis.

A landmark study recently published in March 2025 by JCO Oncology Advances, demonstrates the potential of K-TRACKTM in monitoring treatment response and assessing recurrence risk among 623 Solid-Tumor Patients of six cancer types (lung, colorectal, breast, gastric, liver, or ovarian cancer).(1) SINGAPORE, April 19, 2025 /PRNewswire/ — Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce […]

Gene Solutions Leads the Way in Cancer Early Detection with Asia’s First Clinical Validated Multi-Cancer Blood Test

SINGAPORE, March 26, 2025 /PRNewswire/ — Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. The company’s innovative SPOT-MAS test has become the first multi-cancer screening blood test in Asia to complete large prospective cohort validation, as published in BMC Medicine. This milestone marks a major advancement, enabling large-scale, non-invasive early detection. Gene […]